Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834)

Daniel V.T. Catenacci; Drew Rasco; Jeeyun Lee; Sun Young Rha; Keun Wook Lee; Yung Jue Bang; Johanna Bendell; Peter Enzinger; Neyssa Marina; Hong Xiang; Wei Deng; Janine Powers; Zev A. Wainberg

doi:10.1200/JCO.20.03583

Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834)

Daniel V.T. Catenacci
, Drew Rasco
, Jeeyun Lee
, Sun Young Rha
, Keun Wook Lee
, Yung Jue Bang
, Johanna Bendell
, Peter Enzinger
, Neyssa Marina
, Hong Xiang
, Wei Deng
, Janine Powers
, Zev A. Wainberg

Department of Internal Medicine

Research output: Contribution to journal › Comment/debate

Abstract

The July 20, 2020, article by Catenacci et al, entitled "Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma" (J Clin Oncol 38:2418-2426, 2020), was published with an error.

Original language	English
Pages (from-to)	258
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	39
Issue number	3
DOIs	https://doi.org/10.1200/JCO.20.03583
State	Published - 20 Jan 2021

Access to Document

10.1200/JCO.20.03583

Fingerprint

Dive into the research topics of 'Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834)'. Together they form a unique fingerprint.

Cite this

Catenacci, D. V. T., Rasco, D., Lee, J., Young Rha, S., Lee, K. W., Bang, Y. J., Bendell, J., Enzinger, P., Marina, N., Xiang, H., Deng, W., Powers, J., & Wainberg, Z. A. (2021). Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834). Journal of Clinical Oncology, 39(3), 258. https://doi.org/10.1200/JCO.20.03583

Catenacci, Daniel V.T. ; Rasco, Drew ; Lee, Jeeyun et al. / Erratum : Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834). In: Journal of Clinical Oncology. 2021 ; Vol. 39, No. 3. pp. 258.

@article{b20bf56ca141483f8d36ba7c884c0189,

title = "Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834)",

abstract = "The July 20, 2020, article by Catenacci et al, entitled {"}Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma{"} (J Clin Oncol 38:2418-2426, 2020), was published with an error.",

author = "Catenacci, \{Daniel V.T.\} and Drew Rasco and Jeeyun Lee and \{Young Rha\}, Sun and Lee, \{Keun Wook\} and Bang, \{Yung Jue\} and Johanna Bendell and Peter Enzinger and Neyssa Marina and Hong Xiang and Wei Deng and Janine Powers and Wainberg, \{Zev A.\}",

year = "2021",

month = jan,

day = "20",

doi = "10.1200/JCO.20.03583",

language = "English",

volume = "39",

pages = "258",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

Catenacci, DVT, Rasco, D, Lee, J, Young Rha, S, Lee, KW, Bang, YJ, Bendell, J, Enzinger, P, Marina, N, Xiang, H, Deng, W, Powers, J & Wainberg, ZA 2021, 'Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834)', Journal of Clinical Oncology, vol. 39, no. 3, pp. 258. https://doi.org/10.1200/JCO.20.03583

Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834). / Catenacci, Daniel V.T.; Rasco, Drew; Lee, Jeeyun et al.
In: Journal of Clinical Oncology, Vol. 39, No. 3, 20.01.2021, p. 258.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834)

AU - Catenacci, Daniel V.T.

AU - Rasco, Drew

AU - Lee, Jeeyun

AU - Young Rha, Sun

AU - Lee, Keun Wook

AU - Bang, Yung Jue

AU - Bendell, Johanna

AU - Enzinger, Peter

AU - Marina, Neyssa

AU - Xiang, Hong

AU - Deng, Wei

AU - Powers, Janine

AU - Wainberg, Zev A.

PY - 2021/1/20

Y1 - 2021/1/20

N2 - The July 20, 2020, article by Catenacci et al, entitled "Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma" (J Clin Oncol 38:2418-2426, 2020), was published with an error.

AB - The July 20, 2020, article by Catenacci et al, entitled "Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma" (J Clin Oncol 38:2418-2426, 2020), was published with an error.

UR - https://www.scopus.com/pages/publications/85100228173

U2 - 10.1200/JCO.20.03583

DO - 10.1200/JCO.20.03583

M3 - Comment/debate

C2 - 33450172

AN - SCOPUS:85100228173

SN - 0732-183X

VL - 39

SP - 258

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 3

ER -

Catenacci DVT, Rasco D, Lee J, Young Rha S, Lee KW, Bang YJ et al. Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834). Journal of Clinical Oncology. 2021 Jan 20;39(3):258. doi: 10.1200/JCO.20.03583

Erratum: Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma (Journal of Clinical Oncology (2020) 38 (2418-2426) DOI: 10.1200/JCO.19.01834)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this